Overview

The treatment paradigm of advanced lung cancer has changed in the last several years with the discovery of driver mutations that can be inhibited by specific tyrosine kinase inhibitors. Moreover, the new immunotherapeutic agents – monoclonal antibodies classified as check point inhibitors – have definitely solidified the shift in this paradigm.

The symposium will review the progress in the field of new tyrosine kinase inhibitors (TKI) as well as the use of immunotherapeutic agents in the field of lung cancer and head and neck cancer. It will also examine several issues related to immunotherapeutic agents, i.e. pathology testing for PD-L1 expression, surgical considerations and abscopal effects from radiation.

Head and neck cancer is a complex disease that requires a multidisciplinary input. The symposium will review the management of base-of-skull cancers and rehabilitation issues related to this subset of patients.

Approved for a maximum of 4.5 AMA PRA Category 1 Credits™
Lung Cancer and Head & Neck Cancer Symposium
Saturday, April 2, 2016
Sheraton Overland Park, Overland Park, Kansas

Course Directors
Chao H. Huang, M.D., FACP, Associate Professor, University of Kansas Medical Center, Kansas City, Kansas; Section Chief of Hematology & Oncology at Veterans Administration Medical Center, Kansas City, Missouri
Prakash Neupane, M.D., Associate Professor, University of Kansas Medical Center, Kansas City, Kansas

Target Audience
This symposium is designed for physicians, nurses, pharmacists and health care professionals specializing in lung cancer and head and neck cancer.

Objectives
At completion of this symposium participants should be able to:
• Identify appropriate patients for novel TKIs and management of side effects.
• Discuss the indication for the use of immunotherapy in lung cancer and head and neck cancer.
• Identify and manage the side effects related to immunotherapy.
• Describe the importance of and be able to interpret the pathology testing for PD-L1.
• Review surgical considerations and understand the mechanism of abscopal effects from radiation when using immunotherapy.

University of Kansas Medical Center is an AA/EO Title IX institution.

KU Medical Center
Continuing Education & Professional Development
3901 Rainbow Blvd., MS 4001
Kansas City, KS 66160